[go: up one dir, main page]

DE3587681D1 - Vakzine und Serum für Endotoxin assoziierte Krankheit und Verfahren zur Herstellung derselben sowie Verfahren zur Immunisierung und Behandlung solcher Krankheiten, enttoxifierte Endotoxine und bakterielle Mutante. - Google Patents

Vakzine und Serum für Endotoxin assoziierte Krankheit und Verfahren zur Herstellung derselben sowie Verfahren zur Immunisierung und Behandlung solcher Krankheiten, enttoxifierte Endotoxine und bakterielle Mutante.

Info

Publication number
DE3587681D1
DE3587681D1 DE85104085T DE3587681T DE3587681D1 DE 3587681 D1 DE3587681 D1 DE 3587681D1 DE 85104085 T DE85104085 T DE 85104085T DE 3587681 T DE3587681 T DE 3587681T DE 3587681 D1 DE3587681 D1 DE 3587681D1
Authority
DE
Germany
Prior art keywords
methods
immunizing
endotoxin
serum
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE85104085T
Other languages
English (en)
Other versions
DE3587681T2 (de
Inventor
Ronald F Sprouse
Harold E Garner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Missouri Columbia
Original Assignee
University of Missouri Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Missouri Columbia filed Critical University of Missouri Columbia
Application granted granted Critical
Publication of DE3587681D1 publication Critical patent/DE3587681D1/de
Publication of DE3587681T2 publication Critical patent/DE3587681T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1235—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE3587681T 1984-04-05 1985-04-03 Vakzine und Serum für Endotoxin assoziierte Krankheit und Verfahren zur Herstellung derselben sowie Verfahren zur Immunisierung und Behandlung solcher Krankheiten, enttoxifierte Endotoxine und bakterielle Mutante. Expired - Fee Related DE3587681T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59711584A 1984-04-05 1984-04-05
US69700885A 1985-01-31 1985-01-31

Publications (2)

Publication Number Publication Date
DE3587681D1 true DE3587681D1 (de) 1994-01-27
DE3587681T2 DE3587681T2 (de) 1994-07-07

Family

ID=27082733

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3587681T Expired - Fee Related DE3587681T2 (de) 1984-04-05 1985-04-03 Vakzine und Serum für Endotoxin assoziierte Krankheit und Verfahren zur Herstellung derselben sowie Verfahren zur Immunisierung und Behandlung solcher Krankheiten, enttoxifierte Endotoxine und bakterielle Mutante.

Country Status (10)

Country Link
US (2) US5641492A (de)
EP (2) EP0540063A1 (de)
JP (3) JP2625099B2 (de)
AR (1) AR242903A1 (de)
AU (2) AU589552B2 (de)
CA (1) CA1263306A (de)
DE (1) DE3587681T2 (de)
ES (2) ES8802117A1 (de)
IE (1) IE940698L (de)
PH (1) PH23104A (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
WO1986004352A1 (en) * 1985-01-15 1986-07-31 Unisearch Limited Immunoassay systems for the detection of salmonella
DK140387A (da) * 1986-03-18 1987-09-19 Research Corp Paavisning af haptener ved immunoanalysemetoder
US4789544A (en) * 1986-05-23 1988-12-06 Midcon Labs. Inc. Co-vaccination using non-O-carbohydrate side-chain gram-negative bacteria preparation
IL82624A (en) * 1986-05-23 1993-02-21 Oread Pharmaceutical Inc Compositions for co- vaccination comprising bacterial lipopolysaccharides
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
AU7701098A (en) * 1997-05-28 1998-12-30 Michael A. Apicella Laft mutants of pathogenic gram-negative bacteria
US6682745B1 (en) * 1998-07-28 2004-01-27 Christiaan Antonius Arnoldus Jacobs Use of bacterium for manufacture of a vaccine
DE60007668T2 (de) * 1999-01-26 2004-12-02 Akzo Nobel N.V. Verwendung lebender abgeschwächter Bakterien zur Herstellung eines submukosalen Impstoffes
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
US6379676B2 (en) * 1999-03-10 2002-04-30 Anitox Corporation Enhancing immune response in animals
WO2006130161A2 (en) * 2004-07-21 2006-12-07 The Cornell Research Foundation, Inc. Therapeutic compounds derived from spider venom and their method of use
US9399057B2 (en) 2010-01-28 2016-07-26 Universiteit Gent Salmonella vaccine
EP3185896B1 (de) 2014-06-20 2025-04-02 University of Saskatchewan Exotoxin/thermolysinzusammensetzungen sowie verfahren und verwendung zur vorbeugung und behandlung von hufrehe
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB164622A (en) * 1920-06-11 1921-06-16 C L I Mfg Company Ltd Improvements in lamp and other brackets for use on cycles and motor cycles
US3075883A (en) * 1961-11-08 1963-01-29 Cons Lab Inc Novel parenteral vaccine antigen compositions and methods of making and using
US4029762A (en) * 1971-11-17 1977-06-14 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Lipid A-preparation
GB1560934A (en) * 1975-05-07 1980-02-13 Unilever Ltd Methods for the resistance of non-human mammals to gastro-intestinal disorders
US4148877A (en) * 1975-12-29 1979-04-10 Choay S. A. Fraction capable of inducing in vivo a resistance to bacterial infections, process for obtaining said fraction from bacteria and drugs containing said fraction
FR2393065A1 (fr) * 1977-05-31 1978-12-29 Merieux Inst Procede de separation de lipides d'endotoxines bacteriennes et notamment d'endotoxine de bordetella pertussis
US4567041A (en) * 1977-12-08 1986-01-28 Likhite Vilas V Mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent
US4335107A (en) * 1978-06-05 1982-06-15 Snoeyenbos Glenn H Mixture to protect poultry from salmonella
US4530832A (en) * 1978-12-07 1985-07-23 Schering Corporation Method of vaccination for prevention of Bordetella bronchiseptica infection
FR2466251B1 (fr) * 1979-10-03 1983-03-18 Agronomique Inst Nat Rech Vaccin animal anticolibacillaire, obtention et application
US4327082A (en) * 1979-07-12 1982-04-27 Adcock-Ingram Laboratories Limited Mastitis vaccination
AU529322B2 (en) * 1979-07-27 1983-06-02 Pitman-Moore, Inc. Antigenic compositions
FR2464300B1 (fr) * 1979-08-29 1983-08-05 Agronomique Inst Nat Rech Preparation de souches salmonella abortus ovis et compositions de vaccins les contenant
US4491660A (en) * 1980-01-10 1985-01-01 Abbott Laboratories Matrix polymers for binding endotoxins
IL59663A (en) * 1980-03-19 1983-02-23 Univ Ramot Vaccines obtained from bacterial mutant strains of enterobacteriaceae and pseudomonaceae
US4328210A (en) * 1980-03-31 1982-05-04 Norden Laboratories, Inc. Modified Pasteurella bacteria and vaccines prepared therefrom
US4338298A (en) * 1980-04-04 1982-07-06 Endowment And Research Foundation At Montana State University Vaccine for passive immunization against enteric colibacillosis and method of use
DE3022914A1 (de) * 1980-06-19 1981-12-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verfahren zurgewinnung eines anaphylatoxin und cocytotaxin enthaltenden leukotaxinpraeparates sowie von anaphylatoxin und cocytotaxin in molekular einheitlicher form
NZ201698A (en) * 1981-08-31 1985-12-13 S L Gaffin Composition of antibodies specific to endotoxins
US4530831A (en) * 1982-11-02 1985-07-23 Akzo N.V. Infectious Bursal Disease vaccine
US4582790A (en) * 1983-02-15 1986-04-15 Wisconsin Alumni Research Foundation Monoclonal antibody to angiotension-converting enzyme and methods of preparing and using same
GB8305323D0 (en) * 1983-02-25 1983-03-30 Baylor College Medicine Infectious bovine rhinotracheitis vaccine
US4571336A (en) * 1983-08-25 1986-02-18 Endorphin, Inc. Immune stimulation
US4762712A (en) * 1983-08-31 1988-08-09 Stolle Research & Development Corporation Anti-mastitis polyvalent vaccine, method of administration and method for production thereof
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
US4582798A (en) * 1984-11-23 1986-04-15 Miles Laboratories, Inc. Preparation and use of enzyme-detergent extracted Streptococcus equi vaccine
US4789544A (en) * 1986-05-23 1988-12-06 Midcon Labs. Inc. Co-vaccination using non-O-carbohydrate side-chain gram-negative bacteria preparation

Also Published As

Publication number Publication date
US5961985A (en) 1999-10-05
EP0158282A3 (en) 1988-05-25
JPS6121A (ja) 1986-01-06
DE3587681T2 (de) 1994-07-07
AU589552B2 (en) 1989-10-19
US5641492A (en) 1997-06-24
JPH07252165A (ja) 1995-10-03
EP0158282B1 (de) 1993-12-15
JP2534032B2 (ja) 1996-09-11
JP2625099B2 (ja) 1997-06-25
IE940698L (en) 1985-10-05
CA1263306A (en) 1989-11-28
JP2638755B2 (ja) 1997-08-06
EP0540063A1 (de) 1993-05-05
EP0158282A2 (de) 1985-10-16
ES8802117A1 (es) 1988-04-01
ES550947A0 (es) 1988-04-01
AU634972B2 (en) 1993-03-11
PH23104A (en) 1989-04-10
JPH07250673A (ja) 1995-10-03
ES541955A0 (es) 1988-04-01
AR242903A1 (es) 1993-06-30
AU3910689A (en) 1989-11-23
AU4076785A (en) 1985-10-10
ES8802118A1 (es) 1988-04-01

Similar Documents

Publication Publication Date Title
DE3587681D1 (de) Vakzine und Serum für Endotoxin assoziierte Krankheit und Verfahren zur Herstellung derselben sowie Verfahren zur Immunisierung und Behandlung solcher Krankheiten, enttoxifierte Endotoxine und bakterielle Mutante.
DE3887625D1 (de) Verfahren zur Herstellung von 1,1,1-Trifluorodichlorethan und von 1,1,1,2-Tetrafluorchlorethan.
DE3786891D1 (de) Sehr weicher spinnvliesstoff und verfahren zur herstellung desselben.
DE3855525D1 (de) Verwendung eines Protein gebundenen Polysaccharid Zur Herstellung eines Arzneimittels für die Behandlung von AIDS.
DE3850452D1 (de) Gekrümmte polykarbonatgeschützte Polarisationsschicht und Verfahren zur Herstellung.
DE122005000030I1 (de) Pregna-1, 4-dien-3, 20-dion-16-17-acetal-21-ester,Verfahren zur Herstellung, sowie diese enthaltendepharmazeutische Pr{parate.
DE3583576D1 (de) Kuenstliches blutgefaess und verfahren zur herstellung.
DE3879218D1 (de) Medizinisches instrument und verfahren zur herstellung.
ATE96174T1 (de) Verfahren zur herstellung von avermectine-b und die verwendeten kulturen.
ATE108067T1 (de) Impfstoff und verfahren zur herstellung.
DE69015605D1 (de) Hitzebeständige struktur sowie verfahren zur herstellung.
ATA328286A (de) Zell-linien und verfahren zur herstellung von humanen monoklonalen antikörpern sowie kit und verfahren zur bestimmung der anwesenheit von p.aeruginosa
DE68913394D1 (de) Verfahren zur Herstellung von substituierten Phenoxyethylaminen sowie Zwischenverbindungen.
DE3875575D1 (de) Verfahren und vorrichtung und vorrichtung zur herstellung und behandlung von transfermembranen.
DE69017418D1 (de) Verfahren zur Herstellung von gepfropften Polyolen und daraus erhaltene Polyolen.
IL81370A (en) Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions
ATE43809T1 (de) Keramischer koerper sowie verfahren und form zur herstellung desselben.
DE3778089D1 (de) Verfahren zur herstellung und verwendung fester, pflanzenwirksamer zusammensetzungen.
DE3784518D1 (de) Medizinisches material und verfahren zur herstellung.
DE3885304D1 (de) Zubereitung für zahnbehandlung und verfahren zur herstellung.
EP0674905A3 (de) Bacterin zur Behandlung von Necrophorum-Krankheiten und Verfahren zur Herstellung.
DE3789657D1 (de) Synthetische alkali-metall-alumino-silicate, verfahren und verwendungen, zubereitungen, sowie deren verfahren zur herstellung.
DE68914362D1 (de) Impfstoff, geeignet zur Verhütung bzw. Kontrolle der durch Haemophilus pleuropneumoniae verursachte Schweinekrankheit und Verfahren zu dessen Herstellung.
DE3850177D1 (de) Verfahren zur Herstellung von tertiären Alkyldimethylhalosilanen.
DE3775512D1 (de) Antikoagulans und sein verfahren zur herstellung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee